Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 14/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16574070 | 0.88 | MAPT (0.46) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL16574026 | 0.84 | ALDH1A1 (0.51) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL16573990 | 0.83 | RAB9A (0.47) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL21507805 | 0.83 | MAPT (0.42) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL16574129 | 0.82 | KDM4E (0.46) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL16573989 | 0.81 | RAB9A (0.49) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL21508073 | 0.80 | MAPT (0.42) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL17656949 | 0.80 | MAPT (0.47) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL18713642 | 0.80 | KDM4E (0.39) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL16201981 | 0.79 | MAPT (0.53) | MAPTRAB9AKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| EP-3041842-B1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | KAROS PHARMACEUTICALS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
| US-9750740-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Kanos Pharmaceuticals, Inc. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| US-9512122-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | KAROS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2016-04-07 | — | — | US | disclosed |
| US-9199994-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | KAROS PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | MAPT 4256/4885RAB9A 2533/4885KDM4E 2437/4885 |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | MAPT 4256/4885RAB9A 2533/4885KDM4E 2437/4885 |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | MAPT 4256/4885RAB9A 2533/4885KDM4E 2437/4885 |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | MAPT 4256/4885RAB9A 2533/4885KDM4E 2437/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | MAPT 4256/4885RAB9A 2533/4885KDM4E 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.